| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
8,742 |
6,892 |
$905K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
5,608 |
4,451 |
$740K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,940 |
3,584 |
$399K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,857 |
1,360 |
$292K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,150 |
673 |
$260K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
2,839 |
794 |
$250K |
| 80053 |
Comprehensive metabolic panel |
6,512 |
5,257 |
$250K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,142 |
7,563 |
$247K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
5,405 |
4,803 |
$226K |
| 36415 |
Collection of venous blood by venipuncture |
13,250 |
9,388 |
$154K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,905 |
2,435 |
$151K |
| 80306 |
|
748 |
529 |
$144K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,070 |
698 |
$119K |
| 70450 |
Computed tomography, head or brain; without contrast material |
531 |
478 |
$117K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,062 |
1,498 |
$104K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,080 |
1,866 |
$103K |
| 80076 |
|
1,976 |
1,709 |
$100K |
| 71046 |
Radiologic examination, chest; 2 views |
1,849 |
1,651 |
$94K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,874 |
1,600 |
$88K |
| 94760 |
|
5,127 |
4,063 |
$86K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,384 |
1,964 |
$83K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,616 |
2,800 |
$81K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
1,014 |
339 |
$68K |
| 83880 |
|
992 |
796 |
$67K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,346 |
1,096 |
$66K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
220 |
196 |
$62K |
| 81001 |
|
2,477 |
2,162 |
$61K |
| 80061 |
Lipid panel |
1,044 |
966 |
$59K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
5,152 |
4,562 |
$54K |
| 83735 |
|
3,391 |
2,475 |
$52K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
827 |
773 |
$51K |
| 84484 |
|
2,512 |
1,938 |
$50K |
| 82550 |
|
2,082 |
1,694 |
$44K |
| T1015 |
Clinic visit/encounter, all-inclusive |
545 |
442 |
$41K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
772 |
464 |
$40K |
| 83605 |
|
1,321 |
1,111 |
$39K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,422 |
1,313 |
$37K |
| 84100 |
|
3,159 |
2,355 |
$36K |
| 87634 |
|
314 |
294 |
$35K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,179 |
1,087 |
$34K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,212 |
1,020 |
$29K |
| 83690 |
|
981 |
817 |
$29K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
705 |
596 |
$27K |
| 71045 |
Radiologic examination, chest; single view |
822 |
716 |
$24K |
| 82553 |
|
1,086 |
905 |
$23K |
| 85610 |
|
1,102 |
823 |
$22K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
755 |
650 |
$22K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
253 |
236 |
$21K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
45 |
39 |
$19K |
| 81025 |
|
448 |
382 |
$19K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
382 |
336 |
$19K |
| 82150 |
|
467 |
398 |
$17K |
| 71250 |
|
42 |
42 |
$14K |
| 85730 |
|
660 |
590 |
$13K |
| 81003 |
|
418 |
359 |
$13K |
| 87806 |
|
136 |
113 |
$12K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
652 |
533 |
$11K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
179 |
156 |
$10K |
| 87077 |
|
423 |
362 |
$10K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
196 |
182 |
$10K |
| 86705 |
|
112 |
91 |
$10K |
| 87186 |
|
396 |
339 |
$10K |
| 97162 |
|
98 |
95 |
$9K |
| 86803 |
|
117 |
96 |
$9K |
| 86707 |
|
117 |
94 |
$9K |
| 73564 |
|
148 |
128 |
$9K |
| 86704 |
|
114 |
93 |
$9K |
| 73630 |
|
149 |
140 |
$9K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
14 |
12 |
$9K |
| 86706 |
|
115 |
94 |
$9K |
| 87350 |
|
115 |
93 |
$9K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
159 |
135 |
$8K |
| 87340 |
|
115 |
94 |
$8K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
51 |
49 |
$7K |
| 74019 |
|
47 |
43 |
$7K |
| 96376 |
|
140 |
115 |
$7K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
24 |
24 |
$6K |
| 72110 |
|
75 |
74 |
$6K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
742 |
702 |
$5K |
| 74022 |
|
31 |
28 |
$5K |
| 84145 |
|
144 |
133 |
$5K |
| 84703 |
|
73 |
56 |
$5K |
| 87040 |
|
101 |
92 |
$4K |
| 85379 |
|
210 |
192 |
$4K |
| 86140 |
|
237 |
194 |
$4K |
| 73130 |
|
55 |
51 |
$3K |
| 73610 |
|
55 |
53 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
39 |
28 |
$3K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
67 |
67 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
42 |
16 |
$2K |
| 87070 |
|
45 |
31 |
$2K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
738 |
598 |
$1K |
| 73030 |
|
12 |
12 |
$595.18 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
12 |
12 |
$484.30 |
| 0001A |
|
19 |
17 |
$227.52 |
| 87081 |
|
15 |
15 |
$172.35 |
| 91300 |
|
29 |
20 |
$0.02 |